No Data
No Data
Health Check: How Prudently Does CanSino Biologics (HKG:6185) Use Debt?
CANSINOBIO: Interim Report 2024
The mid-term core indicators continue to be optimized, cansinobio (6185.HK/688185.SH) has entered a path of benign development.
With the gradual fading of the impact of the previous public health incident, the current domestic vaccine industry's competitive landscape is gradually returning to normal, but still faces many challenges and difficulties. Firstly, the global vaccine market presents an obvious oligopoly pattern, with GlaxoSmithKline, Merck, Pfizer and Sanofi accounting for more than 90% of the global vaccine market share. Domestic vaccines urgently need technological breakthroughs to enhance global competitiveness. Secondly, this year, China is facing public health issues such as pertussis and pneumonia, which cannot be ignored. These new trends and challenges have prompted domestic vaccine companies to continuously enrich their product pipelines to meet the new demands of public health.
Hong Kong stock market abnormal | Cansinobio (06185) rose more than 6%, narrowing its losses in the first half of the year by more than 70%, and the revenue from meningococcal vaccines increased by 18%.
Cansinobio (06185) rose more than 6%, as of press time, up 6.13%, at HKD 18.34, with a turnover of HKD 12.7767 million.
Statistics on the abnormal proportion of the Stock Connect in China-Hong Kong Stock Connect on August 30th
Unusual statistics for the proportion of stock connect in Chitong Port | August 29, 2024
2024 Semi-Annual Report
No Data
No Data